BioSpace News Archive

Aeterna Zentaris Inc. announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, announced it will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15.

Resverlogix Corp., a world leader in epigenetics, or gene regulation, announces that its investigational epigenetic therapeutic apabetalone met the primary endpoint in an investigator led pulmonary arterial hypertension pilot study, successfully completing the APPROACH-p trial.

Heska Corporation, a leading provider of advanced veterinary diagnostic and specialty healthcare products, announced the hire of Anthony Providenti to serve as Executive Vice President, Corporate Development.

Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), a bioengineering company developing novel organ regeneration technology based its patented Cellframe™ and Cellspan™ technology, today announced the appointment of Jerry He as an independent director to its Board of Directors, adding strength in the areas of business innovation, strategy and finance.

Biotia, Inc., a company that delivers proprietary analytical software for infectious disease diagnostics, is experiencing rapid adoption by clinical researchers worldwide of its user-friendly software platform for the comprehensive surveillance and deeper insights into COVID-19 viral genetic variants.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21

Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today announced significant progress regarding the regulatory interactions in Europe required to support advancement of the BB-301 development program towards the Phase 1b/2a clinical study in 2022.

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced that the first cohort of healthy participants have been dosed in the Phase 1 clinical trial of its new drug candidate, COR588.

NLS Pharmaceutics Ltd. announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to present a corporate overview and participate in meetings with investors at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.